Praxis Precision Medicines Inc
NASDAQ:PRAX
Net Margin
Praxis Precision Medicines Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Praxis Precision Medicines Inc
NASDAQ:PRAX
|
699.2m USD |
-2 137%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
336.8B USD |
8%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
150.9B USD |
12%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
131B USD |
2%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
126B USD |
-5%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
118.3B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
66.1B USD |
31%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
32.7B EUR |
38%
|
Praxis Precision Medicines Inc
Glance View
In the realm of biotechnology, Praxis Precision Medicines Inc. has emerged as a distinctive player, navigating the intricate path of neuropsychiatric and neurological disorder treatment. Founded with a mission to develop therapies that directly address the underlying causes of brain disorders, Praxis capitalizes on the integration of genetic insights and brain circuitry. This approach fuels the company’s innovative pipeline, which aims to launch first-in-class or best-in-class treatments for conditions often considered unmanageable or neglected. By leveraging deep genetic knowledge and pioneering circuit-based methodologies, Praxis concentrates its research on specific neural pathways in the hope of crafting target-specific drugs, thereby enhancing both efficacy and safety for patients. Praxis Precision Medicines generates revenue primarily through the clinical development and eventual commercialization of its drug candidates. The company invests heavily in research and development, often funded by strategic partnerships, private investments, and public offerings. As Praxis advances its drug candidates through various phases of clinical trials, it also seeks to strike beneficial collaborations with larger pharmaceutical entities, thus securing upfront payments, milestone fees, and royalties. This business model allows Praxis to sustain its scientific endeavors while setting the stage for potential revenue streams, contingent upon the successful approval and market introduction of its innovative therapies. Through this cycle of rigorous R&D and strategic partnerships, Praxis aims to transform its cutting-edge research into tangible medical solutions, contributing to its growth and financial health.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Praxis Precision Medicines Inc's most recent financial statements, the company has Net Margin of -2 137.5%.
You don't have any saved screeners yet